231 related articles for article (PubMed ID: 20890270)
1. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
2. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
3. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
4. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
Weissferdt A; Tang X; Wistuba II; Moran CA
Mod Pathol; 2013 Dec; 26(12):1554-60. PubMed ID: 23787439
[TBL] [Abstract][Full Text] [Related]
9. Lymphoid Enhancer Binding Factor 1 (LEF1) and Paired Box Gene 8 (PAX8): A Limited Immunohistochemistry Panel to Distinguish Solid Pseudopapillary Neoplasms and Pancreatic Neuroendocrine Tumors.
Lu H; Allende D; Liu X; Zhang Y
Appl Immunohistochem Mol Morphol; 2020; 28(10):776-780. PubMed ID: 32723981
[TBL] [Abstract][Full Text] [Related]
10. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs].
Gurevich LE; Proshchina AE; Voronkova IA; Ashevskaya VE; Korosteleva PA; Dolzhansky OV
Arkh Patol; 2019; 81(5):11-21. PubMed ID: 31626200
[TBL] [Abstract][Full Text] [Related]
11. Non-Ductal Tumors of the Pancreas.
Dhillon J
Monogr Clin Cytol; 2020; 26():92-108. PubMed ID: 32987393
[TBL] [Abstract][Full Text] [Related]
12. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
13. α-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Shen Y; Wang Z; Zhu J; Chen Y; Gu W; Liu Q
Ann Diagn Pathol; 2014 Jun; 18(3):146-50. PubMed ID: 24675392
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
15. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10.
Notohara K; Hamazaki S; Tsukayama C; Nakamoto S; Kawabata K; Mizobuchi K; Sakamoto K; Okada S
Am J Surg Pathol; 2000 Oct; 24(10):1361-71. PubMed ID: 11023097
[TBL] [Abstract][Full Text] [Related]
16. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
[TBL] [Abstract][Full Text] [Related]
17. Presentation and outcome of mixed neuroendocrine non-neuroendocrine neoplasms of the pancreas.
Nießen A; Schimmack S; Weber TF; Mayer P; Bergmann F; Hinz U; Büchler MW; Strobel O
Pancreatology; 2021 Jan; 21(1):224-235. PubMed ID: 33309225
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
19. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y; Deng Y; Li S; Zhou X; Chen Y; Ma D; Mao X; Guan Y; Chen J; Meng Y
J Surg Oncol; 2016 Nov; 114(6):697-702. PubMed ID: 27761900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]